prikaz prve stranice dokumenta Efficacy and safety of immunochemotherapy in treatment of follicular Nonhodgkin's lymphoma during COVID-19 pandemic: a study of KroHem, the Croatian cooperative group for hematologic diseases
  Download
PDF 196.63 KB
Conference presentation
Efficacy and safety of immunochemotherapy in treatment of follicular Nonhodgkin's lymphoma during COVID-19 pandemic: a study of KroHem, the Croatian cooperative group for hematologic diseases
At: 27th Congress of the European Hematology Association. Vienna, Austria, 2022. https://doi.org/10.1097/01.HS9.0000847308.18096.87
Galušić, Davor; Bašić-Kinda, Sandra; Pijuk, Anđela; Milunović, Vibor; Dreta, Barbara; Franjić, Neven; Coha, Božena; Sinčić-Petričević, Jasminka; Gaćina, Petar; Pejša, Vlatko; Lucijanić, Marko; Aurer, Igor

Cite this document

Galušić, D., Bašić Kinda, S., Pijuk, A., Milunović, V., Dreta, B., Franjić, N. ... Aurer, I. Efficacy and safety of immunochemotherapy in treatment of follicular Nonhodgkin's lymphoma during COVID-19 pandemic: a study of KroHem, the Croatian cooperative group for hematologic diseases [PowerPoint slides]. Retrieved from https://urn.nsk.hr/urn:nbn:hr:220:272177

Galušić, Davor, et al. "Efficacy and safety of immunochemotherapy in treatment of follicular Nonhodgkin's lymphoma during COVID-19 pandemic: a study of KroHem, the Croatian cooperative group for hematologic diseases." 27th Congress of the European Hematology Association, 09.06.2022.-12.06.2022., Vienna, Austria. Presentation. https://urn.nsk.hr/urn:nbn:hr:220:272177

Galušić, Davor, Sandra Bašić Kinda, Anđela Pijuk, Vibor Milunović, Barbara Dreta, Neven Franjić, Božena Coha, et al. "Efficacy and safety of immunochemotherapy in treatment of follicular Nonhodgkin's lymphoma during COVID-19 pandemic: a study of KroHem, the Croatian cooperative group for hematologic diseases." Presentation at 27th Congress of the European Hematology Association, Vienna, Austria, 09.06.2022.-12.06.2022. https://urn.nsk.hr/urn:nbn:hr:220:272177

Galušić, D., et al. 'Efficacy and safety of immunochemotherapy in treatment of follicular Nonhodgkin's lymphoma during COVID-19 pandemic: a study of KroHem, the Croatian cooperative group for hematologic diseases' [Presentation], 27th Congress of the European Hematology Association. 09.06.2022.-12.06.2022. Available at: https://urn.nsk.hr/urn:nbn:hr:220:272177

Galušić D, Bašić Kinda S, Pijuk A, Milunović V, Dreta B, Franjić N, and sur.. Efficacy and safety of immunochemotherapy in treatment of follicular Nonhodgkin's lymphoma during COVID-19 pandemic: a study of KroHem, the Croatian cooperative group for hematologic diseases. [Presentation] [cited 2024 November 19] Available at: https://urn.nsk.hr/urn:nbn:hr:220:272177

D. Galušić, et al., "Efficacy and safety of immunochemotherapy in treatment of follicular Nonhodgkin's lymphoma during COVID-19 pandemic: a study of KroHem, the Croatian cooperative group for hematologic diseases", presented at: 27th Congress of the European Hematology Association, Vienna, 09.06.2022.-12.06.2022. Available at: https://urn.nsk.hr/urn:nbn:hr:220:272177

Please login to the repository to save this object to your list.
Metadata
Title (english)Efficacy and safety of immunochemotherapy in treatment of follicular Nonhodgkin's lymphoma during COVID-19 pandemic: a study of KroHem, the Croatian cooperative group for hematologic diseases
AuthorDavor Galušić
AuthorSandra Bašić-Kinda
AuthorAnđela Pijuk
AuthorVibor Milunović
AuthorBarbara Dreta
AuthorNeven Franjić
AuthorBožena Coha
AuthorJasminka Sinčić-Petričević
AuthorPetar Gaćina
AuthorVlatko Pejša
AuthorMarko Lucijanić
AuthorIgor Aurer
Author's institution(Sestre milosrdnice University Hospital Center)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Increased COVID-19 mortality in patients with lymphoproliferative disorders was observed in this study. Our group of patients had reduced OS and PFS compared to the GALLIUM trial and SARS‐CoV‐2 infection was the most pronounced risk factor for death. Even though in some studies bendamustine has shown to be less toxic and more effective than CHOP in FL, there are some important pandemic aspects that must be considered. Bendamustine exposure seems to be associated with worse outcome in case of the infection with SARS-CoV-2. These intriguing differences could play important role in treatment approach in COVID-19 pandemic. Future studies investigating hematological malignancies in COVID-19 pandemic are warranted.
Languageenglish
Peer reviewPeer review - international
DOIhttps://doi.org/10.1097/01.HS9.0000847308.18096.87
URN:NBNurn:nbn:hr:220:272177
Presentation date2022
ConferenceTitle: 27th Congress of the European Hematology Association
Acronym: EHA 2022
Location: Vienna, Austria
Organizer: European Hematology Association
Start date: 2022-06-09
End date: 2022-06-12
Assembly type: Poster
Document URLhttps://journals.lww.com/hemasphere/Fulltext/2022/06003/P1110__EFFICACY_AND_SAFETY_OF_IMMUNOCHEMOTHERAPY.1000.aspx
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) icon
Created on2022-09-07 12:13:27